Related Experiment Videos
Rational prescribing for acute bronchiolitis
1Faculty of Medicine and Health Sciences, UAE University, Al Ain.
Insights
Acute bronchiolitis, a common infant respiratory illness, is usually self-limiting. Current management focuses on supportive care, as pharmacological treatments like bronchodilators and antivirals offer limited, often debated, benefits.
Area of Science:
- Pediatrics
- Infectious Diseases
- Respiratory Medicine
Background:
- Acute bronchiolitis is the most frequent lower respiratory tract infection in infants and young children.
- Respiratory Syncytial Virus (RSV) is the primary causative agent in most cases.
- The illness is typically self-limiting, with management focused on supportive care.
Purpose of the Study:
- To review the current management strategies for acute bronchiolitis.
- To evaluate the efficacy and controversies surrounding pharmacological interventions.
- To discuss the cost-effectiveness of various treatment options.
Main Methods:
- Literature review of existing studies on acute bronchiolitis management.
- Analysis of the use and outcomes of pharmacological therapies, including sympathomimetics and ribavirin.
- Discussion of supportive care measures in both outpatient and inpatient settings.
Main Results:
- Supportive care, including fluid intake and minimal handling, is the cornerstone of management.
- Pharmacological therapies, such as inhaled salbutamol (albuterol) and nebulized racemic adrenaline (epinephrine), have shown mixed or unconfirmed results.
- The use of ribavirin is highly debated and generally not recommended for most infants, though it may be considered for those with underlying conditions, with cost-effectiveness concerns.
Conclusions:
- Acute bronchiolitis management primarily relies on supportive care.
- Pharmacological treatments for acute bronchiolitis are largely unproven and often contentious.
- Strict auditing of prescribing practices for bronchodilators, antibiotics, and corticosteroids is recommended to optimize care and reduce costs.
Abstract:
Acute bronchiolitis is the commonest lower respiratory illness of infancy and early childhood, and it is usually associated with respiratory syncytial virus infection. In the majority of infants, the illness is self-limiting and hence management is directed at maintaining fluid intake, minimal handling and close observation. Children who develop apnoea, fatigue and/or feeding difficulties as well as progressive respiratory distress require hospital admission. Oxygen, intravenous fluids and minimal handling are the pillars of hospital management, and less than 1% of hospitalised infants require additional assisted ventilation. Pharmacological therapy of acute bronchiolitis is contentious. Sympathomimetics are the drugs most frequently used. Inhaled salbutamol (albuterol) has been associated with both positive and negative outcomes. Recent work suggests that nebulised racemic adrenaline (epinephrine) may be helpful in reducing respiratory distress, but further work is needed to confirm this finding. The use of the antiviral drug ribavirin (tribavirin) in acute bronchiolitis remains very contentious. The overwhelming majority of infants do not require the drug and debate remains as to its true effectiveness. The literature tends to support its use in patients with underlying heart or lung disease, but the drug may not be cost effective in this setting. However, the costs of ribavirin therapy could be reduced by the implementation of more rigid treatment guidelines. A reduction in the use of bronchodilators, antibiotics and corticosteroids would help to reduce the overall costs of management. To date, acute bronchiolitis has not lent itself to pharmacological treatment and prescribing should therefore be very strictly audited by clinicians.